Adrenal Adenoma, Adrenal Carcinoma, Adrenal Incidentaloma, Aldosteronism, Congenital Adrenal Hyperplasia, Cushing Syndrome, Hypoadrenalism, Pheochromocytoma
Conditions
Brief summary
Epidemiologic studies have revealed a tremendous increase in the prevalence of adrenal associated disease and related mortality worldwide. In order to meet all the therapeutic challenges in adrenal disease in China, CASE was founded in 2020. The objective of CASE is to launch an adrenal disease management model based on the Internet health information platform which allows the application and evaluation of adrenal disease treatment strategies at multiple centers. The proprietary electronic medical database will help the dynamic big-data analysis in epidemiology of adrenal disease, diagnosis, and treatment.
Detailed description
In order to meet all the challenges in the diagnosis and treatment of adrenal diseases in China, CASE was founded in 2020. With advanced medical equipment and Internet of Things (IoT) technology, CASE is committed to creating an online and offline integrated solution for adrenal disease, and for the entire spectrum of adrenal disease, to achieve a more convenient and precise model of care for patients, aiming to establish a platform with diagnosis and treatment of adrenal disease and their long-term follow-up. It allows the application and evaluation of treatment strategies at these centers.
Interventions
None listed
Sponsors
Shanghai Jiao Tong University School of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 75 Years
Inclusion criteria
1. Age ≥ 16 years old and ≤ 75 years 2. Patients diagnosed with adrenal associated diseases, including cushing syndrome, primary aldosteronism, primary hypoadrenalism, congenital adrenal hyperplasia and adrenal adenomas, incidentalomas, and carcinomas, pheochromocytoma, etc. 3. Provide written informed consent 4. Satisfactory compliance
Exclusion criteria
1. Patients with significantly reduced life expectancy (less than 2 years) 2. With Drug abuse 3. With AIDS or syphilis or infectious diseases such as viral tuberculosis in active phase at enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of adrenal diseases in China | through study completion, an average of 1 year |
| Number of participants with complication of adrenal diseases in China | through study completion, an average of 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| concentration of urine cortisol | through study completion, an average of 1 year | — |
| concentration of androstenedione | through study completion, an average of 1 year | — |
| concentration of adrenocorticotropic hormone | through study completion, an average of 1 year | — |
| concentration of 17-hydroxyprogesterone | through study completion, an average of 1 year | — |
| concentration of aldosterone | through study completion, an average of 1 year | — |
| changes in adrenal CT | through study completion, an average of 1 year | — |
| percentage of hypoadrenalism | through study completion, an average of 1 year | — |
| Mental health status | through study completion, an average of 1 year | The symptom checklist-90 will be used to evaluate the changes of participants' psychological state through study completion from 10 aspects, including somatization, obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety, hostility, terror, paranoia, psychotic and others. |
| concentration of metanephrines | through study completion, an average of 1 year | — |
| concentration of cortisol | through study completion, an average of 1 year | — |
Countries
China
Contacts
Primary Contactshouyue SUN, MD
Outcome results
None listed